The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical impact of febrile neutropenia (FN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer.
Erika Paige Hamilton
No relevant relationships to disclose
Donna L. Topping
No relevant relationships to disclose
Jeffrey M. Peppercorn
Employment or Leadership Position - GlaxoSmithKline (I)
Consultant or Advisory Role - Bayer; Genentech
Stock Ownership - GlaxoSmithKline (I)
P. Kelly Marcom
No relevant relationships to disclose
Gretchen Genevieve Kimmick
Honoraria - CHAMBER Foundation
Research Funding - Bionovo; Bristol-Myers Squibb; GlaxoSmithKline; Wyeth
Other Remuneration - AstraZeneca; Genomic Health; Novartis; Pfizer
Erin Duff
No relevant relationships to disclose
Constance T. Cirrincione
No relevant relationships to disclose
Kimberly L. Blackwell
Honoraria - Amgen